KBC Group NV Has $87,000 Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

KBC Group NV raised its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 53.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,151 shares of the company’s stock after purchasing an additional 752 shares during the period. KBC Group NV’s holdings in Kymera Therapeutics were worth $87,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in KYMR. Blue Trust Inc. raised its position in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Kymera Therapeutics during the third quarter worth $61,000. Quarry LP bought a new stake in shares of Kymera Therapeutics during the third quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares during the last quarter. Finally, Integrated Advisors Network LLC bought a new stake in shares of Kymera Therapeutics during the third quarter worth $294,000.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 15.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 target price on the stock. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Truist Financial reaffirmed a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Stephens reaffirmed an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, BTIG Research initiated coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $55.06.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $37.32 on Monday. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of -15.95 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52 week low of $29.24 and a 52 week high of $53.27. The firm has a 50-day moving average price of $41.46 and a two-hundred day moving average price of $44.51.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.